Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM13G5R)

• Drug Name: TRK-170 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Inflammatory bowel disease	DD72	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DM13G5R

Molecule-Related Drug Atlas

Drug(s) Targeting Integrin alpha-4/beta-7 (ITGA4/B7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MLN0002	DMP2LZ8	Crohn disease	DD70	Approved	[3]
PN-943	DMUZLKW	Ulcerative colitis	DD71	Phase 2	[4]
MORF-057	DMS274E	Crohn disease	DD70	Phase 2	[5]
GS-1427	DMDDBG1	Inflammation	1A00-CA43.1	Phase 1	[6]
TR-14035	DMWD39E	Multiple sclerosis	8A40	Discontinued in Phase 1	[7]
R1295	DMT8V9G	Rheumatoid arthritis	FA20	Discontinued in Phase 1	[8]

Drug(s) Targeting Integrin alpha-4/beta-1 (ITGA4/B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AJM-300	DM5K6J4	Crohn disease	DD70	Phase 3	[9]
R411	DMP7J0S	Asthma	CA23	Phase 2	[10]
CDP323	DMXYLTI	Multiple sclerosis	8A40	Phase 2	[11]
Firategrast	DMW2QYT	Multiple sclerosis	8A40	Phase 2	[12]
HMR-1031	DM695QT	Arthritis	FA20	Phase 1	[13]
BIIB107	DMIA57S	Multiple sclerosis	8A40	Phase 1	[14]
TR-14035	DMWD39E	Multiple sclerosis	8A40	Discontinued in Phase 1	[7]
CY-9652	DMPBCLA	Inflammation	1A00-CA43.1	Terminated	[15]
TCS2314	DMBVYQR	Discovery agent	N.A.	Investigative	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Integrin alpha-4/beta-1 (ITGA4/B1)	TT6S84X	ITA4_HUMAN-ITB1_HUMAN	Modulator	[2]
Integrin alpha-4/beta-7 (ITGA4/B7)	TT7ZMI1	ITA4_HUMAN-ITB7_HUMAN	Modulator	[2]

References

• [1] ClinicalTrials.gov (NCT01345799) A Study of TRK-170 for the Treatment of Crohn's Disease. U.S. National Institutes of Health.
• [2] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [3] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [4] Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of alpha4beta7, in Healthy Volunteers. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1263-1278.
• [5] ClinicalTrials.gov (NCT05291689) A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-1). U.S.National Institutes of Health.
• [6] Clinical pipeline report, company report or official report of Gilead
• [7] Pharmacokinetics and metabolism of TR-14035, a novel antagonist of a4ss1/a4ss7 integrin mediated cell adhesion, in rat and dog. Xenobiotica. 2005 Apr;35(4):373-89.
• [8] Vedolizumab: an 47 integrin inhibitor for inflammatory bowel diseases.Ann Pharmacother.2014 Dec;48(12):1629-35.
• [9] Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice. J Crohns Colitis. 2013 Dec;7(11):e533-42.
• [10] Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov. 2010 Oct;9(10):804-20.
• [11] Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study.PLoS One.2013;8(3):e58438.
• [12] Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.Lancet Neurol.2012 Feb;11(2):131-9.
• [13] Pharmacoscintigraphic comparison of HMR 1031, a VLA-4 antagonist, in healthy volunteers following delivery via a nebulizer and a dry powder inhaler. Am J Ther. 2004 Mar-Apr;11(2):103-13.
• [14] ClinicalTrials.gov (NCT04593121) A Phase 1, Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Ascending-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB107 in Healthy Adult Participants. U.S.National Institutes of Health.
• [15] US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions.
• [16] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2580).